Download PDF
Thromb Haemost 2009; 102(02): 389-396
DOI: 10.1160/TH08-11-0732
Animal Models
Schattauer GmbH

Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis

Naoko Watanabe
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
2   Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Hitoshi Ikeda
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
2   Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Yukio Kume
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
,
Yumiko Satoh
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
,
Makoto Kaneko
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
,
Daiya Takai
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
,
Kazuaki Tejima
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
2   Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Masakazu Nagamine
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
,
Hirosato Mashima
2   Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Tomoaki Tomiya
2   Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Eisei Noiri
3   Department of Hemodialysis and Apheresis, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Masao Omata
2   Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
,
Masanori Matsumoto
4   Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan
,
Yoshihiro Fujimura
4   Department of Blood Transfusion Medicine, Nara Medical University, Nara, Japan
,
Yutaka Yatomi
1   Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo Japan
› Author Affiliations
Further Information

Publication History

Received: 11 November 2008

Accepted after major revision: 28 May 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Although hepatic stellate cells, endothelial cells, glomerular podocytes and plateles were reported to be a source of ADAMTS13, it is not clarified which source is involved in the regulation of plasma ADAMTS13 activity. It was demonstrated previously that selective hepatic stellate cell damage in rats caused decreased plasma ADAMTS13 activity.To further elucidate the potential contribution of hepatic stellate cells to the regulation of plasma ADAMTS13 activity, this study examined plasma ADAMTS13 activity when hepatic stellate cells proliferate during the process of liver fibrosis by employing rat models of liver fibrosis due to cholestasis, bile duct ligation, and steatohepatitis, a choline-deficient L-amino acid-defined-diet. ADAMTS13 expression was increased with co-localisation with smooth muscle α-actin, a marker of hepatic stellate cells, in bile duct-ligated livers up to four weeks, in which a close correlation between ADAMTS13 and smooth muscle α-actin mRNA expressions was determined. Plasma ADAMTS13 activity, measured by a sandwich ELISA involving a specific substrate to ADAMTS13, was increased in bile duct-ligated rats with a significant correlation with ADAMTS13 mRNA expression levels in the liver. Furthermore, ADAMTS13 mRNA expression was increased with enhanced mRNA expression in smooth muscle α-actin in the livers of rats fed a choline-deficient L-amino aciddefined-diet for 16 weeks, in which increased plasma ADAMTS13 activity was determined. Thus, increased plasma ADAMTS13 activity in cholestasis and steatohepatitis in rats may be due, at least in part, to enhanced ADAMTS13 production in the liver, suggesting a significant role of hepatic stellate cells in the regulation of plasma ADAMTS13 activity.

Keywords

ADAMTS13 - hepatic stellate cell - smooth muscle α-actin - bile duct ligation - steatohepatitis
 

  • References

  • 1 Furlan M, Robles R, Solenthaler M. et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-3103.
    PubMedGoogle Scholar
  • 2 Banno F, Kokame K, Okuda T. et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006; 107: 3161-3166.
    CrossrefPubMedGoogle Scholar
  • 3 Chauhan AK, Walsh MT, Zhu G. et al. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008; 111: 3452-3457.
    CrossrefPubMedGoogle Scholar
  • 4 Kinoshita S, Yoshioka A, Park YD. et al. UpshawSchulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 2001; 74: 101-108.
    CrossrefPubMedGoogle Scholar
  • 5 Sasahara Y, Kumaki S, Ohashi Y. et al. Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome. Int J Hematol 2001; 74: 109-114.
    CrossrefPubMedGoogle Scholar
  • 6 Hommais A, Rayes J, Houllier A. et al. Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Thromb Haemost 2007; 98: 593-599.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Furlan M, Robles R, Solenthaler M. et al. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-2846.
    PubMedGoogle Scholar
  • 8 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
    CrossrefPubMedGoogle Scholar
  • 9 Yagita M, Uemura M, Nakamura T. et al. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005; 42: 420-421.
    PubMedGoogle Scholar
  • 10 Tsai HM, Raoufi M, Zhou W. et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Luken BM, Turenhout EA, Kaijen PH. et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006; 96: 295-301.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Ono T, Mimuro J, Madoiwa S. et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107: 528-534.
    CrossrefPubMedGoogle Scholar
  • 13 Zheng X, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-41063.
    CrossrefPubMedGoogle Scholar
  • 14 Soejima K, Mimura N, Hirashima M. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem (Tokyo) 2001; 130: 475-480.
    CrossrefPubMedGoogle Scholar
  • 15 Cal S, Obaya AJ, Llamazares M. et al. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 2002; 283: 49-62.
    CrossrefPubMedGoogle Scholar
  • 16 Uemura M, Tatsumi K, Matsumoto M. et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-924.
    CrossrefPubMedGoogle Scholar
  • 17 Niiya M, Uemura M, Zheng XW. et al. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J Thromb Haemost 2006; 04: 1063-1070.
    CrossrefPubMedGoogle Scholar
  • 18 Zhou W, Inada M, Lee TP. et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85: 780-788.
    CrossrefPubMedGoogle Scholar
  • 19 Turner N, Nolasco L, Tao Z. et al. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 04: 1396-1404.
    CrossrefPubMedGoogle Scholar
  • 20 Manea M, Kristoffersson A, Schneppenheim R. et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007; 138: 651-662.
    CrossrefPubMedGoogle Scholar
  • 21 Liu L, Choi H, Bernardo A. et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 03: 2536-2544.
    CrossrefPubMedGoogle Scholar
  • 22 Kume Y, Ikeda H, Inoue M. et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Lett 2007; 581: 1631-1634.
    CrossrefPubMedGoogle Scholar
  • 23 Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
    CrossrefPubMedGoogle Scholar
  • 24 Ikeda H, Wu GY, Wu CH. Lipocytes from fibrotic rat liver have an impaired feedback response to procollagen propeptides. Am J Physiol 1993; 264: G157-162.
    PubMedGoogle Scholar
  • 25 Jin H, Yamamoto N, Uchida K. et al. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2007; 364: 801-807.
    CrossrefPubMedGoogle Scholar
  • 26 Mannucci PM, Canciani MT, Forza I. et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-2735.
    CrossrefPubMedGoogle Scholar
  • 27 Uemura M, Fujimura Y, Matsumoto M. et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-1029.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
    CrossrefPubMedGoogle Scholar
  • 29 Kato S, Matsumoto M, Matsuyama T. et al. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-1452.
    CrossrefPubMedGoogle Scholar
  • 30 Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-311.
    PubMedGoogle Scholar
  • 31 Feys HB, Canciani MT, Peyvandi F. et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-540.
    CrossrefPubMedGoogle Scholar
  • 32 Kokame K, Nobe Y, Kokubo Y. et al. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
    CrossrefPubMedGoogle Scholar
  • 33 Meyer SC, Sulzer I, Lammle B. et al. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 05: 866-867.
    CrossrefPubMedGoogle Scholar
  • 34 Kavakli K, Canciani MT, Mannucci PM. Plasma levels of the von Willebrand factor-cleaving protease in physiological and pathological conditions in children. Pediatr Hematol Oncol 2002; 19: 467-473.
    CrossrefPubMedGoogle Scholar
  • 35 Uemura M, Matsuyama T, Ishikawa M. et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005; 29 (Suppl. 12) 264S-271S.
    CrossrefPubMedGoogle Scholar
  • 36 Lisman T, Bongers TN, Adelmeijer J. et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
    CrossrefPubMedGoogle Scholar